

Review

Pulsed Field Ablation for Atrial Fibrillation: Mechanisms, Advantages, and Limitations

Shali Jiang^{1,2}, Frank Qian³, Shuting Ji^{1,2}, Luohong Li^{1,2}, Qiming Liu¹, Shenghua Zhou¹, Yichao Xiao^{1,*}¹Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, 410011 Changsha, Hunan, China²Xiangya School of Medicine, Central South University, 410013 Changsha, Hunan, China³Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA*Correspondence: yichaoxiao@csu.edu.cn (Yichao Xiao)

Academic Editor: Boyoung Joung

Submitted: 11 October 2023 Revised: 14 November 2023 Accepted: 28 November 2023 Published: 8 April 2024

Abstract

Pulsed field ablation with irreversible electroporation for the treatment of atrial fibrillation involves tissue-specific and non-thermal energy-induced cell necrosis, which helps avoid complications, such as pulmonary vein stenosis, atrial collateral tissue damage, and extensive atrial structural damage, often encountered with traditional thermal ablation. In existing clinical trials, pulsed field ablation has shown excellent effects on pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation. Pulsed field ablation is easy, simple, and quick and can reduce iatrogenic injury. Therefore, the application of pulsed field ablation technology in the treatment of atrial fibrillation has a promising future. Notably, the adjustment of parameters in pulsed field ablation with different ablation catheter systems can strongly affect the area and depth of the necrotic myocardium, which greatly affects the likelihood of atrial fibrillation recurrence and incidence of adverse complications after ablation. In this paper, we review the mechanisms, advantages, and limitations of pulsed field ablation based on the results of a series of previous studies and provide ideas and directions for future research.

Keywords: pulsed electric field; atrial fibrillation; catheter ablation; pulmonary vein isolation; irreversible electroporation

1. Introduction

Atrial fibrillation (AF), recognized as the predominant form of clinical arrhythmia encountered globally [1–3], currently impacts an estimated 35 million individuals. This prevalence is on an upward trajectory, paralleling demographic shifts toward an older population [4]. Achieving and preserving sinus rhythm remains a fundamental objective in managing AF. While pharmacological agents are commonly employed to regulate cardiac rhythm, their application is often limited by adverse effects, particularly in the context of heart failure. Consequently, catheter ablation (CA) has emerged as a vital intervention, especially for those who are either refractory to antiarrhythmic medications or are burdened with heart failure, wherein the safety and tolerability of these drugs are compromised [5,6].

Owing to their higher resting membrane potential, lower action potential amplitude, smaller maximum phase 0 upstroke velocity, and shorter action potential duration than atrial myocardial cells, myocardial cells located in the pulmonary veins (PVs) become a common ectopic trigger in AF [7]. Consequently, PV isolation (PVI) is generally accepted as the cornerstone of invasive AF treatment. Extensive research has delineated the propensity for anatomic irregularities within PVs to precipitate AF, with such variations manifesting in approximately 18% to 45% of AF cases [8]. Concurrently, investigative efforts have elucidated a broader array of extrapulmonary sites that may act

as foci for AF initiation; these include the coronary sinus, left atrial appendage, superior vena cava, and interatrial septum [9,10]. Furthermore, disparities in left atrial morphology, particularly in proximity to the left atrial crest, have been implicated in AF etiology [11]. The integration of these insights is poised to catalyze advancements in AF ablation methodologies. Prospective developments in electrophysiological modalities promise the advent of tailored ablation strategies, facilitating the pinpointing of idiosyncratic arrhythmic origins and the subsequent selection of bespoke ablation catheters for patient-specific therapeutic interventions.

Current strategies for PVI often involve applying thermal energy or cryotherapy through catheters to induce targeted cardiomyocyte coagulation necrosis, which can easily cause damage to the adjacent atrial tissue, resulting in undesirable complications, such as stroke [12,13], atrial esophageal fistula [14], phrenic nerve injury [15], coronary artery damage [16], and PV stenosis [17]. Current large-scale clinical surveys and systematic reviews suggest that the complication rate after pulsed field ablation (PFA) ranges from approximately 2% to 5%, reflecting advancements in ablation technology and patient care protocols [18–20].

PFA is a novel ablation technology that does not use heat or cold energy but involves site-directed intervention using a pulsed electric field (PEF) to make nanoscale hy-






Fig. 1. Mechanism of Cardiomyocyte Death Induced by Electroporation. Electroporation consists of three stages over time: cell membrane charging, pore generation, and pore radius evolution. When the radius of the hydrophilic pore is large enough, the cellular contents will flow out through the pore, which will disrupt intracellular homeostasis and induce programmed cell death.

drophilic micropores appear in the cell membrane of target cells [21], which leads to the expulsion of cellular contents and an imbalance in intracellular homeostasis, eventually inducing programmed cell death. It has strong tissue specificity [22,23] for cardiomyocytes and is typically applied over a relatively short intervention duration, resulting in necrosis within microseconds [24] for PFA versus seconds for conventional thermal ablation [25,26]. Moreover, PEF treatment can cause target cell death without destroying the original intercellular connection, thereby ensuring the structural integrity of the atrial tissue after ablation. This review summarizes the detailed mechanisms and research progress in PFA technology, discusses its advantages over traditional ablation technology, and proposes future strategies to address its current limitations.

2. Mechanism of PEF Ablation for AF

By killing abnormal pacemakers and conduction cells, catheter ablation (CA) can destroy ectopic pacing sites, interrupt abnormal conduction pathways, and regulate cardiac autonomic innervation to restore the normal sinus rhythm. The main cause of paroxysmal AF (PAF) is believed to be sustained firing in the PV area [27–29]. Therefore, it is reliable to treat PAF using ablation technology to cause cellular tissue necrosis in the ostium of the PV, that is, by performing PVI. However, the detailed mechanisms underly-

ing persistent AF (PsAF) remain unclear. Since PsAF has been found to have more complicated triggering and maintenance mechanisms, a single PVI is not effective enough to treat PsAF compared to PAF; therefore, additional ablation targets are often needed to improve the efficiency of CA for PsAF.

PFA is a new technique for AF ablation, which refers to the application of an intermittent high-intensity PEF to a specific type of tissue cell for a very short period (microseconds or nanoseconds), resulting in the electroporation of the cytomembrane. Electroporation can generate hydrophilic pore channels in the lipid bilayer of the cytomembrane, and these membrane channels increase cellular permeability [21]. Increased permeability can be reversible or irreversible, with the former termed reversible electroporation (RE) and the latter termed irreversible electroporation (IRE). There is a stepwise relationship between RE and IRE. IRE is one of the core mechanisms for the necrosis of target cells and tissues during PFA because it causes an irreversible cascade of activated programmed death of targeted cells and tissues [30] (Fig. 1).

With changes in various parameters of the applied PEF, the results of targeted cell tissue intervention may include undetectable electroporation, RE, IRE and thermal damage [31]. Among these, RE and IRE are applied in biotechnology, and thermal damage must be avoided in the construction of irreversible electroporations. A systematic

review [32] suggested that a mild hyperthermic state (temperatures between 40 °C and 50 °C) was observed in 30% of IRE-treated regions, and temperatures exceeding 50 °C were observed in 5% of IRE-treated regions, in which the ablation temperature was far lower than that of thermal ablation, sharply reducing the possibility of thermal damage. PFA, while avoiding the thermal injury commonly associated with conventional ablation techniques, is not without its unique set of complications. One such complication, distinct from thermal ablation, is arcing. This phenomenon occurs when intense current density induces gas accumulation at the electrode-tissue interface, escalating impedance and culminating in dielectric breakdown, a sequence that could precipitate myocardial damage [33]. Fortunately, arcing can be avoided by using non-direct current and optimizing catheter electrodes [34].

3. Experimental Research Progress of PFA

Prior to the application of PFA in human AF ablation, extensive animal model experiments were performed to investigate its safety and feasibility. This study investigated the degree of myocardial tissue necrosis during endocardial and epicardial PFA, the effects of different PEF voltage intensities and pulses on PVI, and the durability of PVI generated by PEF. Data from previous representative animal experiments are summarized in Table 1 (Ref. [22,35–40]).

The experimental results shown in Table 1 indicate that the application of PFA for AF is safe in animals. Moreover, compared with thermal energy ablation, the pathological findings suggest that PFA was better able to preserve the structure of the myocardial tissue and cardiac contractility. Furthermore, preclinical studies have shown that biphasic asymmetric pulses can effectively reduce muscle contractions and decrease the threshold for ablation [41]. Additionally, these experiments showed better AF prognosis with PFA compared to traditional AF ablation techniques [42].

Since 2018, several research teams have applied PFA in clinical AF ablation and further optimized the parameters of cardiac PFA in humans. The results of these clinical trials continue to show the superiority of PFA for AF treatment, including a higher success rate of acute PVI, a higher rate of durable PVI, a shorter operation time, and a lower incidence of adverse complications. The representative clinical trials are summarized in Table 2 (Ref. [24,43–48]).

As shown in Table 2, PFA PVI has a high success rate in achieving and maintaining sinus rhythm. Acute PVI success rates reached 100% in the experiments, and the rates of sustained PVI post-PFA generally exceeded 90% under optimized biphasic electric fields. Some groups with high rates of electrical reconnection were assumed to have inappropriate parameters. For example, one study [43] suggested that a 31 mm catheter could induce lower reconnection rates than a 35 mm catheter, and the group that utilized an electrical field of 2000 V showed apparently higher durable isolation rates than the group that utilized

an electrical field of 1800 V or 1900 V. Contrastingly, in patients with PsAF, the rates of durable PVI post-PFA typically range from 60% to 70%. Recent clinical evaluations of PFA in PsAF cohorts indicate that approximately one-third of patients may experience electrical reconnection following ablation [49–51], a rate comparable to that observed with traditional thermal ablation techniques [52]. Moreover, patients with PFA had a shorter procedure time and fewer adverse events. It is worth noting that the advantages of biphasic PEF have been clearly reflected in comparative tests [24,44], and novel multielectrode catheters have been widely used in clinical experiments; however, epicardial ablation may require more experiments to optimize the operating equipment and parameters compared to endocardial ablation.

A pivotal study [53] “Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF” monitored patients with AF for 12 months after PFA and demonstrated a very low incidence (0.7%) of PFA procedure-related adverse events, including no PV stenosis, phrenic nerve damage, or esophageal damage. Furthermore, in 56.1% (95% confidence interval [CI], 46.7–62.7) of patients with PsAF and 66.2% (95% CI, 57.9–73.2) of patients with PAF, PFA was effective at the 1-year follow-up. In the comparative analysis reported by Reddy *et al.* [54], the efficacy of PFA was juxtaposed against that of conventional thermal ablation in a rigorously controlled clinical setting. Of the cohort, 73.3% (204/278) of patients undergoing PFA and 71.3% (194/272) of those subjected to thermal ablation successfully achieved the primary efficacy endpoint, defined as the absence of atrial fibrillation one year after the procedure. These data suggest equivalence in the therapeutic outcomes between PFA and its thermal counterpart, reinforcing the noninferiority of PFA in the context of atrial fibrillation management.

4. The Superiority of PFA in Treating AF

4.1 Electroporation has Tissue Specificity

PFA is distinguished by its targeted specificity to cardiac myocytes [22], offering a focused therapeutic approach within a concise procedural timeframe. This selectivity is underpinned by empirical studies demonstrating the method’s precision and efficiency [23]. PEF has tissue specificity in inducing IRE; the parameters of PEF can be adjusted to induce IRE in different types of tissue cells, which greatly reduces the incidence of collateral tissue damage in PFA. Table 3 (Ref. [55–60]) shows the electric field threshold of IRE for different types of tissues under certain pulses. The following is a comprehensive analysis of the effects of PEF on ablation sites and adjacent tissue cells in a series of PFA experiments for AF [55–59]; when the electric field environment of a certain tissue reaches its corresponding threshold, it undergoes IRE and initiates apoptosis or necrosis.

Table 1. Representative preclinical trials of PFA for AF.

Experimental subject	Catheter	PEF type and intensity (or voltage)	Ablation position	Acute electrical isolation success	Durable isolation rate	Study follow-up period	Endpoint	and Occurrence of complications and creative points	Ref.
Pigs (weight 60–75 kg)	Circular electroporation ablation catheter	Monophasic	Epicardial side of the left ventricle	-	-	3 months		Epicardial PFA caused extensive and deep myocardial necrosis without causing coronary artery injury.	[39]
4-month-old female Yorkshire-mix pigs (70.66 ± 3.5 kg)	A 9-electrode circular ar-ray PV ablation catheter	Biphasic, 500 V	Right superior PV ostium, LAA, and RAA	100%	-	-		The replacement of fibrosis by PFA was more uniform than that by RFA. Pathological examination showed that epicardial adipose inflammation was significantly reduced and vascular remodeling was decreased. There were no collateral damages.	[35]
Yorkshire swine (60–70 kg)	Lattice-tip catheter with expandable nitinol mesh with 9 surface microelectrodes and thermocouples	Biphasic	Endocardial: R-SPV, SVC, and ICPV	100% (25/25)	61.5% (PF _{LD} : 83.3%) RSPV, 33.3% SVC, and 100% ICPV)	5/6 2 or 4 weeks		Pathological examination showed no damage to mediastinum or pleura. Atrioventricular structural tests after ablation showed no loss of integrity.	[40]
Yorkshire swine (65–90 kg)	A 7.5Fr bidirectional deflectable catheter with an expandable conductive lattice electrode	Biphasic, 400 V/cm	Endocardial: from SVC to IVC	100% (7/7)	85.7% (6/7)	18–37 days		PEF during ablation was not sufficient to cause damage to phrenic nerve fibers.	[38]
Yorkshire swine	A 7.5Fr circular catheter having 10 electrodes with individual irrigation pores	Biphasic, 1800 V	Endocardial: along the posterior wall from SVC to IVC	100% (12/12)	91.7% (11/12)	30 days		The phrenic nerve and esophagus showed no injury in pathological observation. No obvious bubbles and electric sparks were produced during ablation.	[36]
Swines	A multielectrode circular IRE catheter with 10 ablation electrodes	Biphasic	Endocardial: RIPV, RSPV, and SVC	100%	100% (subchronic), 100% (chronic)	Subchronic (7 ± 3 days); Chronic (30 ± 3 days)		After ablation, myocardial fibers and cardiomyocytes were necrotic, but the structure of myocardial tissue was preserved.	[37]
Female Yorkshire swine (60–70 kg)	Yorkshire swine field deployed in flower pose	Multielectrode pulsed ablation catheter	Monophasic, 800~1800 V and biphasic, 800~1800 V	Endocardial: PV and SVC	Monophasic: 100%; Biphasic: 100%	Monophasic: 55.6% (1/7 SVC, 9/11 PV); Biphasic: 100% (6/6 SVC, 12/12 PV)	10 weeks	No pulmonary vein stenosis was reported. Biphasic PFA had more advantages in durable PVI than monophasic PFA.	[22]

Summary of related core parameters of PEF, effect of electrical isolation, and safety of ablation in animal experiments with PFA. PFA, pulsed field ablation; PEF, pulsed electric field; AF, atrial fibrillation. Isolation success, if without special label, it indicated PVI rate; PVI, pulmonary vein isolation; PV, pulmonary vein; LAA, left atrial appendage; RAA, right atrial appendage; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein; SVC, superior vena cava; ICPV, inferior common pulmonary vein; IVC, inferior vena cava; PF_{HD}, high-dose pulsed field; PF_{LD}, low-dose pulsed field; SPV, superior pulmonary vein; RFA, radiofrequency ablation; IRE, irreversible electroporation; Subchronic, the PFA was evaluated over 7 ± 3 days from ablation; Chronic, the PFA was evaluated over 30 ± 3 days from ablation.

Table 2. Representative clinical trials of PFA for AF.

Experimental subject	Catheter	PEF type and intensity (or voltage)	Ablation position	Acute electrical isolation success rate	Durable isolation rate	Study endpoint	Follow-up period	Occurrence of complications and creative points	Ref.
Patients with symptomatic paroxysmal AF resistant to at least one antiarrhythmic drug	A pentaspline catheter (flower configuration) containing 5 splines, each with 4 electrodes	Biphasic, 900–2500 V	Endocardial: The ring-shaped area of the LA-PV junction	100% (15/15)	-	-	-	One month after PFA.	[46]
Patients with symptomatic paroxysmal AF resistant to class I to IV antiarrhythmic medications	A pentaspline catheter (flower configuration) containing 5 splines, each with 4 electrodes	Monophasic, 900–1000 V; Biphasic, 1800–2000 V	Endocardial: the ostium of the left superior PV (left) and the right inferior PV (right)	100% (15 in monophasic; 66 in biphasic)	45% (monophasic), 43% (biphasic 1), 56% (biphasic 2), 100% (biphasic 3)	A composite of major safety events	75 days (PEFCAT) or 90 days (IMPULSE) the index ablation procedure	No recurrence of symptoms and ablation complications were detected after operation. Biphasic electric field did better in PVI.	[24]
Patients with paroxysmal AF resistant to at least one class I to IV antiarrhythmic drug	A pentaspline catheter (basket/flower configuration) containing 5 splines, each with 4 electrodes	Monophasic, 900–1000 V; Early biphasic, 1800–2000 V; Optimized biphasic, 1800–2000 V	Endocardial: cavotricuspid isthmus	100% (57 in monophasic; 223 in early biphasic; 195 in optimized biphasic)	45% (monophasic), 84% (early biphasic), 96% (optimized biphasic) (after 93.0 ± 30.1 days)	Incidence of early and late onset serious adverse events which were procedure related as determined by the independent Clinical Events Committee	30 days, 75 days (PEFCAT) or 90 days (IMPULSE study), 6 months, and 12 months	No significant complications were detected during the one year follow-up, and only 7 patients had recurrent AF, which was not triggered by PV.	[44]
Patients between 18 and 75 years of age with documented symptomatic persistent AF (AF duration: 7–365 days) refractory or intolerant to at least one Class I/III antiarrhythmic agents	A pentaspline catheter (basket/flower configuration) containing 5 splines, each with 4 electrodes	Biphasic, 1600–2000 V (optimized by previous studies)	Endocardial: cavotricuspid isthmus and LAPW	100% (both PV isolation and LAPW isolation)	96% (82/85); 100% (22/22) (after 76–90 days)	A composite of major safety events	Repeated invasive mapping at 75 days after the index procedure	No significant complications were found during follow-up. PFA had a good and durable effect of electrical isolation in patients with persistent AF.	[47]
Patients with symptomatic paroxysmal or persistent AF	A pentaspline catheter (basket/flower configuration)	Biphasic, 1800–2000 V	Endocardial: cavotricuspid isthmus	100% (137/137)	90.4% (Paroxysmal AF), 60.3% (Persistent AF) (after 1 year)	The primary endpoint was electrical PVI	1 year	No obvious adverse reactions were detected. RIPV may require the PFA to be applied several times to achieve isolation. Atropine reduced the duration of post-PFA asystole and heart block.	[48]

Table 2. Continued.

Experimental subject	Catheter	PEF type and intensity (or voltage)	Ablation position (or tion)	Acute electrical success	Electrical isolation rate	Durable isolation rate	Study endpoint	Follow-up period	Occurrence of complications and creative points	Ref.
Patients with symptomatic persistent AF after first ablation	A pentaspline catheter (basal/flower configuration)	Biphasic, 1800 V; Biphasic, 1900 V; Biphasic, 2000 V	Endocardial: RSPV, RIPV, LSPV, LIPV, and LCPV	100% (25/25)	90.9% in the 2000 V and 1900 V groups)	(10/11 64.2% (9/14 in the 1800 V and 1900 V groups)	The rate and distribution of PV reconnection, the features of current atrial tachycardia, and IS-APW (%) after the current pentaspline PFA catheter-guided PVI. ISAPW(%) = (isolated PW surface area)/(total LAPW surface area) × 100	4.8 ± 3.6 months	A single case of postprocedural Dressler's syndrome was observed 4 weeks after the second ablation. The use of 31 mm catheter was supposed to be associated with a lower reconnection rate. In trend, LSPV was the vein with the most frequent reconnection.	[43]
Patients aged 18–70 years with a diagnosis of paroxysmal AF	A flexible linear catheter incorporating a guidewire lumen	Biphasic, 900–2500 V	Epicardial: encircling the posterior LA and the 4 PVs	86% (6/7)	-	-	(1) the inability to isolate all targeted PVs (assessed for entrance and, where assessable, exit block) during the index ablation procedure or (2) ablation using a non-study device to isolate any PV	1 month	No adverse events were reported during one month of postoperative follow-up. In the only case where electrical isolation failed, the patient could not be operated on for technical reasons.	[46]
Patients 18–80 years of age undergoing first-time CA of paroxysmal or persistent AF that failed at least one antiarrhythmic drug (class I or III)	A 9-gold circular electrode array	Biphasic, 500–1500 V	Endocardial: near the level of the PV carina	100% (38/38)	-	-	(1) the inability to isolate all targeted PVs (assessed for entrance and, where assessable, exit block) during the index ablation procedure or (2) ablation using a non-study device to isolate any PV	1 month	During 30 days of follow-up, no complications related to the PFA system occurred. Only one serious procedure-related event related to vascular access was reported.	[45]

Summary of relevant core parameters, effects of electrical isolation, and duration, safety, and feasibility of ablation procedures in a PFA clinical trial. AF, atrial fibrillation; PFA, pulsed field ablation; PEF, pulsed electric field; Isolation success, if without special label, indicated PVI rate; PVI, pulmonary vein isolation; PV, pulmonary vein; LA, left atrium; LAPW, left atrium posterior wall; ISAPW%, ratio of the isolated-to total surface area on PW; LSPV, left superior PV; LIPV, left inferior PV; RIPV, right inferior PV; RSPV, right superior PV; LCPV, left common PV; IMPULSE, a safety and feasibility study of the IOWA approach endocardial ablation system to treat atrial fibrillation; PEF-CAT, a safety and feasibility study of the FARAPULSE endocardial ablation system to treat paroxysmal atrial fibrillation; PEF-CAT II, expanded safety and feasibility study of the FARAPULSE endocardial multi ablation system to treat paroxysmal atrial fibrillation.

Table 3. The electric field intensity threshold of irreversible electroporation (IRE) for different types of tissue.

Tissue Type	Electric field intensity threshold of IRE (V/cm)	Pulses (μ s)	Ref.
Myocardium	750	100	[55]
Vascular smooth muscle	1750	100	[56]
Nerve	1000	50	[57]
Liver	805	100	[58]
Kidney	575 \pm 67	100	[59]
Pancreas	506 \pm 66	70	[60]

4.1.1 Myocardium

According to the mechanism of electroporation, different electric field intensities cause varying electroporation effects, and the sensitivity of certain tissues to electric field intensities varies. This may be due to cell size, cell metabolic activity, and PEF pulses. During atrial fibrillation ablation procedures, the strategic targeting of cardiomyocytes is essential, with the objective of selectively ablating these cells while concurrently conserving the integrity of neighboring structures. These include the vasculature, nerve fibers, adipose tissue, smooth muscle, and mucosal layers within the cardiac milieu and in proximal organs such as the esophagus, which are critical to preserve to minimize collateral damage. Cardiomyocytes are most sensitive to IRE at a certain pulse. An electroporation experiment on cardiomyocytes (H9C2) showed that effective myocardial injury occurred when the intensity of PEF was greater than 375 V/cm [61]. Therefore, PFA has distinct tissue specificity and can preferentially ablate myocardial tissue while protecting other collateral structures (such as the esophagus and phrenic nerve) from injury.

4.1.2 Esophagus

Because the esophagus is adjacent to the posterior part of the left atrium (LA), collateral damage to the esophagus can easily occur during ablation of the left atrial posterior wall (LAPW), leading to atrial esophageal fistula (AEF), which is the most serious complication of CA. In a study [62] of 190 patients with AEF, 80.82% developed AEF within 30 days after ablation, and the overall mortality was 63.16%. Ablation experiments in pig models have shown that the application of PFA through the aorta or inferior vena cava, which is adjacent to the esophagus, does not cause esophageal injury [35,63]. However, if PFA is applied directly to the esophagus, it can cause transmural cell death around the ablation sites. However, owing to the complete structure and function of the extracellular matrix, it is postulated that the esophagus may possess the capacity for self-repair following PFA [64]. Although PFA is nonthermal, it generates a negligible amount of heat. Fortunately, the histological morphology shows that the thermal lesion of the esophagus is confined to the muscular layer and does not spread to the epithelial and mucosal layers, as radiofrequency ablation (RFA) does [65–68].

4.1.3 Pulmonary Veins

Most AF is caused by anomalous pacing sites at PVs, and it has been found that durable PVI is associated with a lower rate of AF recurrence after CA [69]; therefore, durable PVI is the key to successful AF ablation. Despite the widespread use of CA in PVI, PV stenosis caused by CA remains a common problem [70]. PFA appears to be a promising method to resolve this issue. In a previous study using a canine model [71], the extent of PV stenosis induced by PFA and RFA was compared using the cross-sectional area after ablation, and the results showed that PFA significantly reduced the risk of PV stenosis. Subsequently, animal experiments have shown that the likelihood of PV stenosis caused by PFA is extremely low [35,72]. In addition, in the clinical trials mentioned in Table 2, the initial success rate of PVI was 100%, and there were no reported cases of PV stenosis. Kuroki [73] directly reanalyzed 299 PVs from 80 patients with AF and compared the extent of PV stenosis in patients with PAF treated with RFA and PFA in four different trials and found that 9.0% (15 of 166), 1.8% (3 of 166), and 1.2% (2 of 166) of PVs from patients treated with RFA turned out to be mild, moderate, or severe narrowing, respectively, while in patients treated with PFA, no cases of PV narrowing or stenosis were detected.

4.1.4 Coronary Artery

In a systematic review of CA-related coronary injuries, different vascular lesions, including vasospasm-related coronary occlusion, coronary artery dissection, and plaque rupture, occurred near the ablation site [74]. In thermal ablation (cryoballoon ablation and RFA), damage can be minimized by heating or cooling the blood flow to protect the coronary arteries surrounding the ablation sites. For example, some animal experiments have successfully minimized heat-induced damage to the coronary artery endothelium during RFA using intracoronary irrigation with chilled saline [75]. However, when the lesion is too close to blood vessels, this protective strategy fails.

Fortunately, PFA-induced tissue damage is nonthermal and noncontact, which greatly reduces the risk of coronary arterial injury. In a study on coronary artery injury using a porcine model [76], no intimal hyperplasia or signs of stenosis were observed in the group with epicardial IRE on the left anterior descending artery. Meanwhile, in the group with epicardial IRE at the base of the left ventricle, 5 of 56 inside and 1 of 47 outside lesions had intimal hy-

perplasia but with <50% area stenosis. Furthermore, connective tissue growth factor expression was observed in the scar tissue but not in the fibrotic tissue directly surrounding the arteries, indicating that the arteries were indeed spared from tissue damage and remodeling. Even in the presence of large myocardial lesions, the coronary arteries remained free of clinically relevant damage 3 weeks after epicardial IRE ablation. Another study on swine [77] also suggested that direct epicardial PFA on coronary arteries created myocardial lesions but also caused neointimal hyperplasia, inducing chronic mild stenosis and acute moderate spasm of the coronary arteries. These studies indicated that coronary artery damage caused by PFA is normally induced by intimal hyperplasia and is always mild or moderate, which cannot induce long-term coronary artery dysfunction. In the future, it may be possible to reduce the risk of coronary artery spasms by inhibiting intimal hyperplasia.

During PFA procedures, instances of coronary spasm have been frequently reported, with these spasms typically presenting as reversible and not leading to fatal outcomes [78,79]. Research suggests that ablation in close proximity to coronary arteries heightens the risk of such spasms, yet they seldom escalate to myocardial infarction [80]. Prophylactic use of nitroglycerin has shown efficacy in the prevention of these spasms [81]. The transient nature of coronary spasms observed with PFA may be due to the procedure's ability to induce reversible electroporation and permeabilization in both cardiomyocytes and adjacent vascular endothelial cells, which does not result in permanent tissue damage [79].

4.1.5 Phrenic Nerve

Similar to other anatomically adjacent tissues, the phrenic nerve is susceptible to thermally induced damage from CA. IRE has also been shown to cause minor damage to the nerves surrounding the ablation site [82], but animal experiments [83] have shown that only acute paralysis of the phrenic nerve, without evidence of chronic injury, occurs with therapeutic PFA. However, several recent animal experiments and clinical trials have shown that PFA does not lead to clinically significant phrenic nerve injury [36,45]. A study [84] of 18 patients with AF indicated that serum nerve injury biomarkers did not change preablation, immediately postablation, or 24 h after ablation. Furthermore, a clinical case report [85] including three patients aged 55–81 years who underwent PFA for symptomatic AF indicated that induced phrenic nerve palsy lasted less than 1 min and was followed by spontaneous full recovery in all cases. The pathophysiological mechanism underlying transient phrenic nerve dysfunction has been identified as hyperpolarization of the phrenic nerves. Further research is needed to resolve the connection between IRE and hyperpolarization, which may be related to electroconformational changes in voltage-gated ion channels or Ca^{2+} ion flow induced by the electric field of IRE.

In conclusion, PFA has good tissue specificity and can effectively prevent a series of collateral tissue injury complications associated with traditional thermal ablation. Contrasts drawn from clinical trials [54,86] reveal that PFA may offer a reduction in operative duration yet necessitate an extended period of fluoroscopy relative to traditional thermal ablation. The incidence of perioperative complications and the rates of AF recurrence within the first post-operative year did not significantly differ between the two modalities. This could be attributed to the nascent stage of proficiency in PFA application. There is a consensus in the literature suggesting the need for more extensive randomized controlled trials with prolonged monitoring to definitively ascertain the comparative long-term effectiveness and safety profiles of PFA versus thermal ablation.

4.2 PFA has an Effective and Durable Effect on PVI in Patients with PAF

PFA has obvious advantages in PVI compared to a series of traditional thermal ablation techniques, including RFA and cryoballoon ablation [87]. This advantage is reflected not only in the improved safety and reduced complications of ablation but also in the upfront success rate and durability of PVI, which can have important long-term prognostic implications for AF.

Compared with thermal ablation, PFA showed obvious advantages in single-shot PVI. In a 2022 experimental report [88], the success rate of single-shot PVI induced using PFA in 191 patients with AF was 99.5% (779/783). Comparatively, the isolation rates of single emission and single mapping of cryoballoon ablation and laser balloon ablation were 86% and 91.6%, respectively [89,90]. Moreover, a different, less supportive guidewire was used in all four instances. Using a modified catheter, all the remaining PVs were isolated after a second series of PFA. Subsequent electrophysiological assessments have elucidated the effects of PFA, demonstrating substantial lesion formation around the pulmonary veins and achieving consistent isolation of the left atrial posterior wall. Notably, this is accomplished with a minimal reduction in tissue voltage, attesting to the precision of PFA [91]. While the incidence is reduced, the phenomenon of early pulmonary vein reconnections post-PFA does manifest. These reconnections tend to localize to specific anatomical regions: the right carina, the anterior segment of the right superior pulmonary vein (RSPV), the posteroinferior quadrant of the right inferior pulmonary vein (RIPV), the posterior sector of the left superior pulmonary vein (LSPV), and the posteroinferior area of the left inferior pulmonary vein (LIPV). Such a distribution mirrors the patterns often observed following thermal ablation procedures. A possible explanation for this similarity may lie in the variable myocardial wall thickness across these regions, coupled with the inherent challenges associated with catheter maneuverability [50,92].

Over time, owing to incomplete tissue ablation, recovery of the PV electrical connection and recurrence of AF are challenges faced by all types of ablation techniques. Therefore, long-term maintenance of sinus rhythm after PVI is also an important metric for evaluating the relative efficacy of different ablation techniques. In individuals with PAF unresponsive to antiarrhythmic drug therapy, PFA has been administered to achieve sustained PVI [93]. Follow-up investigations, conducted at a median interval of 84 days, revealed cardiac voltage maps consistent with those observed immediately postprocedure in a cohort of 20 patients. This continuity suggests that the ablation-induced isolation of pulmonary vein antral regions may be enduring, hinting at PFA's capability for establishing long-lasting PVI in PAF patients. In contrast, current data do not demonstrate a comparable advantage for PFA in achieving enduring PVI among patients with PsAF [49–51].

Although some unresolved issues remain, the feasibility, safety, and durability of PFA for PVI have been demonstrated, and PFA has improved tissue safety compared with conventional thermal ablation. Researchers have made strides in multiple domains to further improve the efficacy and safety of PFA PVI. Currently, a more effective method is the use of a multipolar catheter instead of a traditional single catheter combined with biphasic PEF for ablation [94,95].

4.3 PFA is Ultrarapid and has a Protective Effect on Atrial Structure

The PFA has obvious advantages in terms of ablation speed. In recent clinical trials [24,44,46], the operation time of PFA has generally been controlled at approximately 95–25 min. According to a recently published multinational survey [78] of clinical PFA applications, the average procedure time was 65 min (range, 38–215 min), including pre- and/or postablation electroanatomical mapping in some patients. The fluoroscopy time was 13.7 min (range 4.5–33).

PFA has a protective effect on atrial structure. In experimental studies, in addition to mild inflammation in the early postprocedural stage, the atrial site only showed loss of cardiomyocytes and smooth muscle cells, without destruction of the original cardiac tissue structure, replacement with fibrocytes, formation of new blood vessels, or deposition of collagen [37]. This finding indicates that PFA can maintain normal atrial morphology. Studies have shown that during the atrial recovery period after PFA, the physiological process of chronic fibrosis is less involved [96], which can maintain the tissue compliance of the LA and preserve the cardiac structure and contractile and diastolic functions as much as possible.

5. Limitations of PFA in the Treatment of AF

5.1 Uncertainty of the Ablation Catheter, Electric Field Parameters, and Ablation Positions

The main limitations of the clinical application of AF ablation using PEF are that the selection of an appropriate catheter, optimal parameters of PEF, and ablation positions with high safety have not yet been standardized [64], and these factors can affect the reliability of AF ablation to different degrees. However, with the increasing application of PFA in animal models of AF, these problems will gradually be resolved. In this case, we should analyze the limitations of the current PFA technology in terms of therapeutic effects, which can be used as a reference and research direction for future technical optimization to ensure the efficacy and safety of PFA.

5.2 Unknown Characteristics of Cardiac Lesions after PFA

The application of PEF in CA for AF produces unique ablation characteristics in the circumferential venous sinus isolation zone. In 2022, a study [97] described the extent of the PVI zone formed by a single PEF. In this study, 40 patients with PAF or PsAF who had not undergone ablation therapy were treated with PFA (flower/basket-shaped catheter) for the first time. During the 190-day postoperative follow-up, AF recurred in only four patients (15%). High-density three-dimensional electrical mapping was used to compare measurements before and after ablation. Finally, researchers found that an inadequate isolation area was most common in the anterior vena cava segment of the left PV; the greatest area of inadequate isolation in the PV sinus segment was also located anteriorly in the left PV and anteriorly and inferiorly in the right inferior PV. At the same time, an enlarged left atrial isolation zone was most common and widespread in the posterior wall and apical areas on both sides of the LA. In theory, the expanded electrical isolation zone can block the generation and conduction of ectopic triggers more thoroughly but introduces other potential risks. According to prior clinical experience with RFA, an expanded ablation area can result in the following three risks: (1) injury to adjacent tissues, such as the esophagus and phrenic nerve; (2) excessive atrial scarring resulting in loss of systolic function; and (3) separation of normal atrial electrical conduction and formation of a reentrant pathway leading to malignant tachycardia. The first risk can be avoided by adjusting the PEF parameters and improving tissue specificity. However, the second and third are significant risks of additional regional injuries, and special attention should be given to the protection of LAPW myocardium and the roof of the left atrium during PFA PVI.

5.3 Microbubbles Produced during Ablation

Gaseous microemboli during cardiac ablation have long been reported. In previous thermal ablation studies, the generation of microbubbles was associated with rapid carbonization, and gas production was associated with tis-

sue injury and necrosis [64]. Although PEF does not use thermal energy to cause necrosis of tissues and cells, microbubbles still occur. Microbubbles generated by PFA can disappear in a short period without obvious physiological effects [98]. Research delineating the safety profile of PFA has produced mixed outcomes regarding cerebrovascular risks. Initial experimental models have suggested that the microbubbles produced during PFA do not precipitate cerebral embolic events [99,100]. In contrast, data emerging from recent clinical trials indicate the occurrence of asymptomatic cerebral embolisms in a subset of patients following PFA [53,54,101]. The potential for such embolisms to occlude critical cerebral vasculature—and thereby precipitate severe neurological sequelae—underscores the imperative for rigorous investigation into prophylactic strategies that might mitigate this risk.

5.4 Abnormal Coronary Microvascular Function during PFA

Monophasic PEF ablation causes skeletal muscle contractions and subtle changes in systemic hemodynamics. Some patients with AF have coronary microvascular dysfunction in the absence of obstructive coronary artery disease, which further leads to reduced myocardial perfusion flow and cardiac dysfunction. Perceived AF symptoms cannot often be relieved after undergoing successful ablation [102]. Coronary dysfunction is likely to induce heart failure, which can lead to recurrent arrhythmias, including AF. Therefore, numerous studies have recently adopted biphasic wave PFA to avoid the risk of coronary artery dysfunction [41]. Recent studies have also shown that preoperative nitroglycerin intervention can prevent the occurrence of coronary artery vasospasm [81], which may become a means to reduce the risk of periprocedural myocardial injury during future AF ablations.

5.5 Insufficient Clinical Experience with PFA

Thus far, most trials on PFA only had a few samples and were not randomized controlled trials. The durability of PFA PVI and the rate of recurrent AF must be confirmed through long-term event surveillance. Currently, these two data types are relatively scarce and require further research.

Moreover, it is still unclear how PEF affects other cardiac intervention devices, such as artificial valves, cardiac pacemakers, and coronary stents. The acquisition of long-term outcomes from multicenter randomized trials conducted on targeted clinical groups is imperative to validate the efficacy and safety of PFA. An earlier study [103] indicated that metal intracoronary stents in proximity to the ablation device simply “amplify” the vessel-induced distortion of the E-field with tissue between the artery and ablation electrode, probably being moderately heated during this distortion but not damaged thermally. Initial research into PFA for individuals with cardiac implantable electronic devices (CIEDs) indicates a favorable safety profile. Small-scale clinical investigations have reported that PFA does not

compromise the functionality or structural integrity of pacemakers and defibrillators. Specifically, in a cohort of six patients, device performance remained stable post-PFA [104]. Similarly, PFA yielded positive arrhythmia control in a patient with an ICD (implantable cardioverter-defibrillator) [105]. Further studies, including a trial with 20 CIED recipients, suggest that avoiding direct contact between the PFA catheter and the implanted device is essential. Adhering to this precaution, PFA appears to be a viable option for diverse CIED types, using catheters sized 31 mm or 35 mm and energy outputs ranging from 1.9 kV to 2.0 V [106].

The current landscape of PFA for the management of AF shows promise; however, it is imperative to acknowledge that the long-term efficacy and safety profile of this modality remain to be comprehensively characterized. The paucity of extended follow-up data from large-scale, randomized controlled trials poses a notable limitation to the robust evaluation of PFA. This gap in evidence may have consequential implications for clinical decision-making, potentially hindering the development of standardized protocols and the optimization of patient outcomes. This underscores the exigent need for multicenter studies with longitudinal monitoring to substantiate the long-term therapeutic value of PFA and to affirm its role in the evolving paradigm of AF treatment. Such investigations are crucial not only for validating the preliminary positive outcomes but also for ensuring that the benefits of PFA outweigh any delayed adverse effects, thereby enabling informed clinical judgments and enhancing patient care.

6. Direction for Technical Optimization of PFA for Clinical AF Treatment

According to Joule’s law of electric current, PFA produces not only electrical effects on tissues and cells but also certain thermal effects during the procedure, which can cause thermally induced damage to cells and tissues [107,108]. At present, the main method for reducing thermally induced damage during ablation is the use of low-frequency PEF. However, according to the mechanism of PFA mentioned above, the formation of IRE depends on PEF parameters, including the electric field frequency. Therefore, one of the main directions for the optimization of PFA technology is to select appropriate PEF parameters to avoid thermal damage and other adverse complications during IRE. Furthermore, the optimization of PEF parameters can partially resolve the technical limitations discussed earlier. However, because of the unclear mechanism of PsAF, the current treatment effect of PVI alone for PsAF is not ideal; therefore, it is necessary to study the efficacy of targeting additional ablation targets to improve the long-term maintenance of sinus rhythm. In addition to optimizing the parameters related to PFA, improving the application of PEF in clinical AF ablation is an important future direction. Fig. 2 summarizes the potential directions for further optimization of PFA technology.

Pulsed Electric Field Ablation




Fig. 2. Future Directions for Optimizing Pulsed Field Ablation-Associated Parameters. LA, left atrium; PV, pulmonary vein; LAPW, left atrium posterior wall.


6.1 Optimization of the Ablation System Parameters

In the study of PFA applied for PVI, there are many indications that multipolar CA is superior to single CA, even if the parameters of PFA need to be adjusted. Various types of novel multipolar catheters are available. Currently, flower-shaped and basket-shaped catheters are the most common [44,46]. Special lattice electrodes [26,38,109], circular multipolar catheters [36], and flexible linear epicardial catheters [46] have also been used in some experiments. Table 4 (Ref. [24,44–46,109]) illustrates several novel forms of multipole catheters and their performance in the respective experiments. However, an experiment [110] showed that different discharge modes of multipolar catheters would affect the distribution of the myocardial electric field, resulting in different widths and depths of myocardial lesions, which can influence the ultimate efficacy of PVI. Therefore, an important consideration for further optimization of PFA technology is to achieve the needed depth of the lesion while controlling the area of the myocardial lesion by adjusting the discharge mode of the electrodes as part of the multipolar electric field. In addition to improving the catheter form, optimization of the catheter mapping system is also crucial [111]. PEF has the capability to form cardiac lesions without necessitating direct electrode-tissue contact. However, the proximity of the electrode to

myocardial tissue significantly influences lesion size, with closer contact resulting in larger lesions. Notably, the variance in lesion dimensions relative to electrode distance is less pronounced with biphasic PEF compared to monophasic PEF [112]. A robust linear relationship exists between lesion depth and electrode-tissue proximity, achieving maximal lesion depth at zero distance [113]. Incorporating a precise mapping system can streamline the ablation process, enabling accurate localization of arrhythmogenic foci and facilitating control over lesion extent through careful management of electrode proximity.

Meanwhile, although the current research on PFA does not involve the study of electrode-tissue orientation, previous ablation operations in various fields seem to default to placing the electrode parallel to the tissue, which may be difficult to achieve accurately in some complex organ locations. However, in the study of parameters affecting IRE, electrode-tissue orientation was found to affect the scope and depth of tissue necrosis and the voltage threshold of IRE [114]. This finding is very important for the optimization of parameters in the ablation process.

Table 4. Novel catheters in PFA and related respective trials.

	Flower/Basket-shaped catheter	multielectrode	Circular multielectrode catheter	Lattice electrode catheter	Flexible linear epicardial catheter
Catheter conceptual image					
Catheter description	The 12-F over-the-wire PFA ablation catheter has 5 splines that each contain 4 electrodes, and it can be deployed in either a flower petal or basket configuration. When fully deployed into a flower pose, the diameter of the distal portion is 31 mm		An over-the-wire, circular array catheter with 9 gold electrodes (electrode length, 3 mm; 20° forward tilted array with a diameter of 25 mm; 9F shaft)	The lattice catheter is a 7.5Fr bidirectional deflectable catheter with an expandable conductive lattice electrode, containing 9 mini-electrodes/temperature sensors (0.7 mm diameter) that are uniformly distributed on its surface (The catheter is inserted into the sheath in a collapsed form, but once in the heart, the lattice expands to a 9 mm diameter spherical configuration)	This is a flexible linear epicardial catheter and incorporates a guidewire lumen. 30 Electrodes for PEF ablation energy delivery are distributed in the midportion of the catheter—the portion that wraps around the PVs and posterior LA
Experimental subject	Patients with symptomatic paroxysmal AF resistant to class I to IV antiarrhythmic medications		Patients 18–80 years of age undergoing first-time CA of paroxysmal or persistent AF that failed at least one antiarrhythmic drug (class I or III)	Yorkshire swine (65–90 kg)	Patients with symptomatic paroxysmal AF refractory to or intolerant of at least one antiarrhythmic drug
Ablation position	Endocardial: the ostium of the right inferior PV		Endocardial: near the level of the PV carina	Endocardial: from SVC to IVC	Epicardial: encircling the posterior LA and the four PVs
Preablation mapping technique	Preprocedure CT or intracardiac echocardiography (ICE) (Acunav, Siemens, Munich, Germany)		Fluoroscopy or intracardiac echocardiography imaging	Fluoroscopy imaging by lattice electrode catheter	Compatible electroanatomical mapping system (Orion and Rhythmia, Boston Scientific, St. Paul, MN, USA)
PEF type	Biphasic		Biphasic	Biphasic	Biphasic
Electric field intensity or voltage	1800–2000 V		500–1500 V	400 V/cm	2100–2400 V
Results	There were no postoperative adverse events. The acute PVI rate was 100%, and the durable PVI rate under optimized waveforms was 96%		The acute PVI rate was 100%. No adverse events occurred 30 days after the operation. The ablation time was significantly shorter than that of RFA	There was little damage to phrenic nerve and esophagus while durable PVI was formed	There was no PV stenosis, arrhythmia, or pericardial effusion after ablation. The acute PVI rate was 100%
Ref.	[24,44]		[45]	[109]	[46]

Summary of novel PFA catheters and representative experiments. LA, left atrium; PFA, pulsed field ablation; PEF, pulsed electric field; AF, atrial fibrillation; CA, catheter ablation; PV, pulmonary vein; PVI, pulmonary vein isolation; SVC, superior vena cava; IVC, inferior vena cava; CT, computed tomography; RFA, radiofrequency ablation.

6.2 Optimization of the PEF Parameters

The meticulous calibration of PEF parameters is integral to achieving ablation specificity, emphasizing the importance of establishing thresholds for the myocardium and surrounding tissues to propel PFA advancements for AF. Optimal thresholds—those precipitating over 80% reduction in cell viability—have been identified, with cardiomyocytes and myocardial fibroblasts exhibiting susceptibility to cell death at an electric field intensity of 1000 V/cm and a pulse quantity of 50 [57].

Moreover, the literature indicates a preference for biphasic short pulses in PFA PVI due to their enhanced efficacy and reduced propensity for muscle contraction, thus preserving atrial architecture post-ablation. Notably, achieving a comparable PVI effect with biphasic short pulses necessitates voltages surpassing 1000 V/cm, unlike monophasic long PEF, which bears implications for potential thermal damage [115]. This necessitates precise PEF parameterization to balance the therapeutic benefits with safety concerns.

Meanwhile, Howard *et al.* [113] showed that the proximity between the electrode and tissue could affect the depth and offset width of the tissue lesion when using a biphasic electric field for ablation. The depth and offset width of the tissue lesion were linearly related to the electrode-tissue proximity; that is, the greater the distance between the electrode and tissue, the smaller the depth and offset width of the necrosis. When the distance was zero, the depth and offset width of necrosis was the maximum. Therefore, while adjusting the PEF parameters, it is possible to control the degree of myocardial necrosis by adjusting the proximity between the electrode and the tissue. The closer the electrode and the tissue, the higher the possibility of achieving myocardial transmural necrosis, while at the same time, the offset width of the necrotic area will increase.

Moreover, in the treatment of AF, the anisotropic electrical conductivity caused by fiber orientation cannot be ignored. According to one study [116], there is a significant difference in the size of the surface ablation area, ablation isosurface, and ablation volume between anisotropic and isotropic electrical conductivity. Consequently, to develop a more targeted restricted ablation zone, it is necessary to establish an electrically refined cardiac model with anisotropic and isotropic electrical conductivities.

6.3 Determination of Optimal AF Ablation Positions

The effect of PFA on PVI in the treatment of PAF is widely recognized. PVs play a crucial role in the initiation and maintenance of AF, particularly PAF [117]. However, because of the complexity of the mechanism of PsAF, simple PVI often cannot achieve a sustained therapeutic effect; therefore, it is still necessary to find new ablation targets to improve the prognostic effect of PsAF ablation. PFA exhibits more limited tissue penetration than conventional thermal ablation, necessitating the identification of supple-

mental ablation targets. While thermal ablation for AF is effective due in part to its impact on the autonomic nervous system by targeting ganglionated plexi (GP), PFA may not achieve the same extent of intramyocardial autonomic nerve ablation, calling into question its thoroughness and persistence [118,119].

Many studies have shown that LAPW can be used as a reliable new target for the ablation of PsAF [120,121]. In an earlier study that included LAPW as a target for PFA, 21 patients undergoing ablation did not have serious complications; the durable isolation rate of LAPW was 100%, the durable PVI rate was 96%, and no recurrence of AF was reported during the 76- to 90-day follow-up [47]. Reliable clinical experiments have also shown that the application of LAPW ablation in the treatment of PsAF does not damage the systolic function of LA [122] and has high feasibility and safety. Concerning PFA's efficacy, achieving comprehensive electrical isolation of LAPW can be challenging. Although recent small-scale trials have shown promising control of arrhythmias post-LAPW PFA [123], the long-term effectiveness and durability of these outcomes warrant confirmation through larger, randomized studies.

In addition to LAPW, another investigator focused on the Marshall bundle and developed the Marshall-Plan ablation protocol [124]. In this protocol, the left atrial sites were targeted sequentially as follows: the coronary sinus and vein of the Marshall musculature, PVI, and anatomical isthmus (mitral, roof, and cavotricuspid isthmus). The patients recruited in this study had a history of long-term PsAF, and the results showed that the maintenance rate of sinus rhythm 12 months after a single ablation was >70% without the use of antiarrhythmic drugs, indicating the high feasibility of this new ablation protocol for the treatment of PsAF. Mitral isthmus PFA has emerged as a viable approach for managing PsAF [80] and is particularly beneficial in cases involving left atrial reentrant tachycardia. However, the applicability of multipolar PFA catheters for mitral isthmus and anterior line ablation may be limited. Focal PFA catheters have been shown to be potentially more suited for these specific ablation targets [125].

The key to finding new ablation targets lies in an in-depth understanding of the electrophysiological mechanism of PsAF. It is now believed that the occurrence and perpetuation of PsAF result from the existence of multiple focal triggers and reentrant pathways in the atrium. Studies have suggested the presence of persistent abnormal activation lesions in the LAPW and three intermittent activation lesions located in the right posterior wall of the atrium. The abnormal conduction pathway had five breaches, two in the PVs, one in the top region of the right atrium, and two in the free wall of the LA [126]. All of these positions may be potential novel ablation targets for AF. Furthermore, it has been found that the formation of an epithelial adipose tissue inflammatory microenvironment, fibrosis, infiltration of atrial tissue, autonomic dysfunction, and oxidative stress

are crucial mechanisms that trigger and maintain AF [127]; thus, epithelial adipose tissue may be a novel target for the clinical treatment of AF.

6.4 Mode Optimization of PEF Application in Ablation

6.4.1 Combination of Thermal Ablation and PFA

In view of the limitations of the current single-energy source CA, researchers have innovatively combined different modalities to compensate for each other's shortcomings and achieve better therapeutic efficacy. One study [26] combined RFA and PFA and alternately used these two forms of energy for ablation during catheter intervention. A novel lattice tip ablation catheter with a compressible 9 mm Nitinol tip was used in the experiment, which could perform focal RFA or PFA damage within 2–5 s. This innovative hybrid ablation technique showed a success rate of PVI similar to that of the traditional single form of ablation. Another study [128] combined PFA with ultralow temperature cryoablation, which induced an extended lesion depth beyond cryoablation without causing muscle contractions or microbubbles.

By combining the tissue safety of PFA and the rich clinical success of thermal ablation, the safety of the procedure is also highly guaranteed, but its clinical application requires further exploration.

6.4.2 Epicardial PFA

Traditional ablation positions are typically located in the endocardium. To reduce invasive injury to patients and avoid vascular embolization caused by endovascular operations, researchers attempted epicardial ablation during the era of thermal ablation. Nevertheless, because of the thick fat and muscle layers extending from the epicardium to the endocardium, the experimental results were not satisfactory. Moreover, thermal ablation of the epicardium is more likely to damage the tissue structures near the atrium [129]. Notably, later studies on PsAF found that local atrial abnormal excitation waves could break through the atrial wall, penetrate to the epicardium, and spread from the focal point of the epicardium in all directions, leading to electrical separation of the endocardium and epicardium, resulting in a higher incidence of PsAF [130–132]. Therefore, there is an urgent need to develop a feasible and safe technique for the ablation of ganglionated plexi embedded within epicardial fat to block abnormal electrical conduction in the epicardium.

The advent of PFA seems to provide a solution to this problem because IRE induced by PEF is tissue specific; therefore, it can be applied for epicardial ablation without fear of damage to the surrounding tissues. Initial experiments with epicardial GP ablation via radiofrequency in canine models revealed an augmented risk for atrial arrhythmias post-procedure, a phenomenon attributed to potential imbalances in autonomic reinnervation. This finding raises the consideration of similar arrhythmic vulnerabilities po-

tentially manifesting after epicardial PFA [133]. A study [134] in a pig model showed that epicardial ablation under PEF produced good transmural myocardial damage without adverse events. Subsequent clinical investigations have corroborated the procedural safety and practicability of epicardial PFA for GP modulation. These studies demonstrate the technique's ability to alter cardiac autonomic nervous system dynamics during surgical interventions without significant complications [46,135]. Furthermore, according to computer modeling of epicardial PFA [136], the PEF zone was almost entirely circumscribed by the epicardial fat layer, while the myocardial incidence was extremely low. Full torso and limited-domain computer models for epicardial PFA [137] indicate that the electrical field is mainly limited to the target site (PEF zone with lengths of 25.79–29.00 mm, depths of 5.98–7.02 mm, and maximum widths of 8.75–10.57 mm) and is practically negligible in adjacent organs (<30 V/cm and <36 V/cm in the esophagus and lungs, respectively), with the 400 V/cm isoline being used to estimate the "PEF zone". While preliminary data affirm the safety of epicardial PFA for ANS (autonomic nervous system) modulation in GP ablation, the true impact on cardiac autonomic function and its efficacy in reducing atrial fibrillation incidence remain to be conclusively determined. Comprehensive, randomized studies are imperative to ascertain the clinical significance of this intervention. Moreover, the incidence of arrhythmias subsequent to certain epicardial ablation procedures necessitates careful consideration [133,135].

7. Conclusions

PFA is an emerging ablation technology for AF with excellent potential. Numerous studies have shown that PFA has an equivalent effect compared with thermal ablation on the establishment of durable PVI and can reduce the occurrence of PV stenosis and collateral damage during both PAF and PsAF ablation procedures. Furthermore, PEF intervention can better protect the atrial structure, avoid extensive damage to the atrial wall, and thereby enhance cardiac reserve. As more experimental and clinical studies are conducted, the existing technical parameters of PFA can be further optimized.

Given the aging global population, which in turn leads to a higher incidence of AF and associated cardiovascular comorbidities, additional research to better address the current limitations, unresolved issues, and unanswered questions associated with PFA is crucial to maximize the potential of this revolutionary technology for the treatment of AF. It is important for future research to construct an electrically refined cardiac model, optimize the discharge mode, establish a novel ablation mode, and observe PFA in a specific population.

Abbreviations

CA, catheter ablation; IRE, irreversible electroporation; LA, left atrium; LAPW, left atrium posterior wall; PAF, paroxysmal atrial fibrillation; PEF, pulsed electric field; PFA, pulsed field ablation; PsAF, persistent atrial fibrillation; PVI, pulmonary vein isolation; PVs, pulmonary veins; RE, reversible electroporation; RFA, radiofrequency ablation.

Author Contributions

SJia: Conceptualization; Writing-original draft; Writing-review & editing. FQ: Conceptualization; Writing-review & editing; Supervision. SJi: Conceptualization; Writing-review & editing. LL: Conceptualization; Writing-review & editing. SZ and QL: Conceptualization; Writing-review & editing; Supervision. YX: Conceptualization; Writing-review & editing; Supervision; Funding acquisition. All the authors have read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate

Not applicable.

Acknowledgment

[Biorender.com](https://www.biorender.com) was used to create the graphical abstract. Ms. Weichu Liu, master in the Department of Physics of Beijing University of Aeronautics and Astronautics, provided us with consulting assistance on physical parameters.

Funding

This paper was supported by the Clinical Medical Technology Innovation Guidance Project of Hunan Science and Technology Agency (2021SK53519).

Conflict of Interest

The authors declare no conflict of interest.

References

- [1] Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, *et al.* 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *European Heart Journal*. 2021; 42: 373–498.
- [2] Chan NY, Orchard J, Agbayani MJ, Boddington D, Chao TF, Johar S, *et al.* 2021 Asia Pacific Heart Rhythm Society (APHRS) practice guidance on atrial fibrillation screening. *Journal of Arrhythmia*. 2021; 38: 31–49.
- [3] Lévy S, Steinbeck G, Santini L, Nabauer M, Maceda DP, Kantharia BK, *et al.* Management of atrial fibrillation: two decades of progress - a scientific statement from the European Cardiac Arrhythmia Society. *Journal of Interventional Cardiac Electrophysiology*. 2022; 65: 287–326.
- [4] Chung MK, Refaat M, Shen WK, Kutyla V, Cha YM, Di Biase L, *et al.* Atrial Fibrillation: JACC Council Perspectives. *Journal of the American College of Cardiology*. 2020; 75: 1689–1713.
- [5] Carlisle MA, Fudim M, DeVore AD, Piccini JP. Heart Failure and Atrial Fibrillation, Like Fire and Fury. *JACC. Heart Failure*. 2019; 7: 447–456.
- [6] Sayed A, Awad AK, Abdelfattah OM, Elsayed M, Herzallah K, Marine JE, *et al.* The impact of catheter ablation in patient's heart failure and atrial fibrillation: a meta-analysis of randomized clinical trials. *Journal of Interventional Cardiac Electrophysiology*. 2023; 66: 1487–1497.
- [7] Cheniti G, Vlachos K, Pambrun T, Hooks D, Frontera A, Takigawa M, *et al.* Atrial Fibrillation Mechanisms and Implications for Catheter Ablation. *Frontiers in Physiology*. 2018; 9: 1458.
- [8] Wang W, Buehler D, Hamzei A, Wang X, Yuan X. Comprehensive surgical approach to treat atrial fibrillation in patients with variant pulmonary venous anatomy. *The Journal of Thoracic and Cardiovascular Surgery*. 2013; 145: 790–795.
- [9] Della Rocca DG, Di Biase L, Mohanty S, Trivedi C, Gianni C, Romero J, *et al.* Targeting non-pulmonary vein triggers in persistent atrial fibrillation: results from a prospective, multicentre, observational registry. *Europace*. 2021; 23: 1939–1949.
- [10] Kim D, Hwang T, Kim M, Yu HT, Kim TH, Uhm JS, *et al.* Extra-Pulmonary Vein Triggers at *de novo* and the Repeat Atrial Fibrillation Catheter Ablation. *Frontiers in Cardiovascular Medicine*. 2021; 8: 759967.
- [11] Gagyi RB, Szegedi N, Simon J, Wijchers S, Bhagwandien R, Kong MH, *et al.* Left atrial anatomical variations correlate with atrial fibrillation sources near the left atrial ridge. *Frontiers in Cardiovascular Medicine*. 2022; 9: 928384.
- [12] Gaita F, Anselmino M. Silent Cerebral Events During Catheter Ablation for Atrial Fibrillation: Not Yet to Be Forgotten. *JACC. Clinical Electrophysiology*. 2018; 4: 1610–1612.
- [13] Miki K, Nakano M, Aizawa K, Hasebe Y, Kimura Y, Morosawa S, *et al.* Risk factors and localization of silent cerebral infarction in patients with atrial fibrillation. *Heart Rhythm*. 2019; 16: 1305–1313.
- [14] Kapur S, Barbhuiya C, Deneke T, Michaud GF. Esophageal Injury and Atrioesophageal Fistula Caused by Ablation for Atrial Fibrillation. *Circulation*. 2017; 136: 1247–1255.
- [15] Sacher F, Monahan KH, Thomas SP, Davidson N, Adragao P, Sanders P, *et al.* Phrenic nerve injury after atrial fibrillation catheter ablation: characterization and outcome in a multicenter study. *Journal of the American College of Cardiology*. 2006; 47: 2498–2503.
- [16] Castaño A, Crawford T, Yamazaki M, Avula UMR, Kalifa J. Coronary artery pathophysiology after radiofrequency catheter ablation: review and perspectives. *Heart Rhythm*. 2011; 8: 1975–1980.
- [17] Kuck KH, Fink T, Metzner A. Pulmonary Vein Stenosis and Occlusion Following Catheter Ablation of Atrial Fibrillation: Still Worth Worrying About? *JACC. Cardiovascular Interventions*. 2018; 11: 1640–1641.
- [18] Ngo L, Ali A, Ganesan A, Woodman R, Adams R, Ranasinghe I. Ten-year trends in mortality and complications following catheter ablation of atrial fibrillation. *European Heart Journal. Quality of Care & Clinical Outcomes*. 2022; 8: 398–408.
- [19] Gupta A, Perera T, Ganesan A, Sullivan T, Lau DH, Roberts-Thomson KC, *et al.* Complications of catheter ablation of atrial fibrillation: a systematic review. *Circulation. Arrhythmia and Electrophysiology*. 2013; 6: 1082–1088.
- [20] Jafry AH, Akhtar KH, Khan JA, Clifton S, Reese J, Sami KN, *et al.* Safety and feasibility of same-day discharge for catheter ablation of atrial fibrillation: a systematic review and meta-analysis.

- Journal of Interventional Cardiac Electrophysiology. 2022; 65: 803–811.
- [21] Kotnik T, Rems L, Tarek M, Miklavčič D. Membrane Electroporation and Electroporabilization: Mechanisms and Models. *Annual Review of Biophysics*. 2019; 48: 63–91.
 - [22] Koruth J, Kuroki K, Iwasawa J, Enomoto Y, Viswanathan R, Brose R, *et al.* Preclinical Evaluation of Pulsed Field Ablation: Electrophysiological and Histological Assessment of Thoracic Vein Isolation. *Circulation. Arrhythmia and Electrophysiology*. 2019; 12: e007781.
 - [23] Casciola M, Keck D, Feaster TK, Blinova K. Human cardiomyocytes are more susceptible to irreversible electroporation by pulsed electric field than human esophageal cells. *Physiological Reports*. 2022; 10: e15493.
 - [24] Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H, *et al.* Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. *Journal of the American College of Cardiology*. 2019; 74: 315–326.
 - [25] Müller J, Nentwich K, Berkovitz A, Ene E, Sonne K, Zhuravlev V, *et al.* Acute oesophageal safety and long-term follow-up of AI-guided high-power short-duration with 50 W for atrial fibrillation ablation. *Europace*. 2023; 25: 1379–1391.
 - [26] Reddy VY, Anter E, Rackauskas G, Peichl P, Koruth JS, Petru J, *et al.* Lattice-Tip Focal Ablation Catheter That Toggles Between Radiofrequency and Pulsed Field Energy to Treat Atrial Fibrillation: A First-in-Human Trial. *Circulation. Arrhythmia and Electrophysiology*. 2020; 13: e008718.
 - [27] Po SS, Li Y, Tang D, Liu H, Geng N, Jackman WM, *et al.* Rapid and stable re-entry within the pulmonary vein as a mechanism initiating paroxysmal atrial fibrillation. *Journal of the American College of Cardiology*. 2005; 45: 1871–1877.
 - [28] Po SS, Scherlag BJ, Yamanashi WS, Edwards J, Zhou J, Wu R, *et al.* Experimental model for paroxysmal atrial fibrillation arising at the pulmonary vein-atrial junctions. *Heart Rhythm*. 2006; 3: 201–208.
 - [29] Atienza F, Jalife J. Reentry and atrial fibrillation. *Heart Rhythm*. 2007; 4: S13–S16.
 - [30] Wittkamp FHM, van Es R, Neven K. Electroporation and its Relevance for Cardiac Catheter Ablation. *JACC. Clinical Electrophysiology*. 2018; 4: 977–986.
 - [31] Kotnik T, Frey W, Sack M, Haberl Meglič S, Peterka M, Miklavčič D. Electroporation-based applications in biotechnology. *Trends in Biotechnology*. 2015; 33: 480–488.
 - [32] Agnass P, van Veldhuisen E, van Gemert MJC, van der Geld CWM, van Lienden KP, van Gulik TM, *et al.* Mathematical modeling of the thermal effects of irreversible electroporation for *in vitro*, *in vivo*, and clinical use: a systematic review. *International Journal of Hyperthermia*. 2020; 37: 486–505.
 - [33] Bardy GH, Coltorti F, Stewart RB, Greene HL, Ivey TD. Catheter-mediated electrical ablation: the relation between current and pulse width on voltage breakdown and shock-wave generation. *Circulation Research*. 1988; 63: 409–414.
 - [34] van Es R, Groen MHA, Stehouwer M, Doevendans PA, Wittkamp FHM, Neven K. In vitro analysis of the origin and characteristics of gaseous microemboli during catheter electroporation ablation. *Journal of Cardiovascular Electrophysiology*. 2019; 30: 2071–2079.
 - [35] Stewart MT, Haines DE, Verma A, Kirchhof N, Barka N, Grassl E, *et al.* Intracardiac pulsed field ablation: Proof of feasibility in a chronic porcine model. *Heart Rhythm*. 2019; 16: 754–764.
 - [36] Yavin H, Brem E, Zilberman I, Shapira-Daniels A, Datta K, Govari A, *et al.* Circular Multielectrode Pulsed Field Ablation Catheter Lasso Pulsed Field Ablation: Lesion Characteristics, Durability, and Effect on Neighboring Structures. *Circulation. Arrhythmia and Electrophysiology*. 2021; 14: e009229.
 - [37] Grimaldi M, Di Monaco A, Gomez T, Berman D, Datta K, Sharma T, *et al.* Time Course of Irreversible Electroporation Lesion Development Through Short- and Long-Term Follow-Up in Pulsed-Field Ablation-Treated Hearts. *Circulation. Arrhythmia and Electrophysiology*. 2022; 15: e010661.
 - [38] Kawamura I, Reddy VY, Wang BJ, Dukkupati SR, Chaudhry HW, Santos-Gallego CG, *et al.* Pulsed Field Ablation of the Porcine Ventricle Using a Focal Lattice-Tip Catheter. *Circulation. Arrhythmia and Electrophysiology*. 2022; 15: e011120.
 - [39] Neven K, van Driel V, van Wessel H, van Es R, du Pré B, Doevendans PA, *et al.* Safety and feasibility of closed chest epicardial catheter ablation using electroporation. *Circulation. Arrhythmia and Electrophysiology*. 2014; 7: 913–919.
 - [40] Koruth JS, Kuroki K, Kawamura I, Stoffregen WC, Dukkupati SR, Neuzil P, *et al.* Focal Pulsed Field Ablation for Pulmonary Vein Isolation and Linear Atrial Lesions: A Preclinical Assessment of Safety and Durability. *Circulation. Arrhythmia and Electrophysiology*. 2020; 13: e008716.
 - [41] Bi S, Jia F, Lv C, He Q, Xu X, Xue Z, *et al.* Preclinical Study of Biphasic Asymmetric Pulsed Field Ablation. *Frontiers in Cardiovascular Medicine*. 2022; 9: 859480.
 - [42] Sugrue A, Vaidya V, Witt C, DeSimone CV, Yasin O, Maor E, *et al.* Irreversible electroporation for catheter-based cardiac ablation: a systematic review of the preclinical experience. *Journal of Interventional Cardiac Electrophysiology*. 2019; 55: 251–265.
 - [43] Tohoku S, Chun KRJ, Bordignon S, Chen S, Schaack D, Urbanek L, *et al.* Findings from repeat ablation using high-density mapping after pulmonary vein isolation with pulsed field ablation. *Europace*. 2023; 25: 433–440.
 - [44] Reddy VY, Dukkupati SR, Neuzil P, Anic A, Petru J, Funosako M, *et al.* Pulsed Field Ablation of Paroxysmal Atrial Fibrillation: 1-Year Outcomes of IMPULSE, PEFCAT, and PEFCAT II. *JACC. Clinical Electrophysiology*. 2021; 7: 614–627.
 - [45] Verma A, Boersma L, Haines DE, Natale A, Marchlinski FE, Sanders P, *et al.* First-in-Human Experience and Acute Procedural Outcomes Using a Novel Pulsed Field Ablation System: The PULSED AF Pilot Trial. *Circulation. Arrhythmia and Electrophysiology*. 2022; 15: e010168.
 - [46] Reddy VY, Koruth J, Jais P, Petru J, Timko F, Skalsky I, *et al.* Ablation of Atrial Fibrillation With Pulsed Electric Fields: An Ultra-Rapid, Tissue-Selective Modality for Cardiac Ablation. *JACC. Clinical Electrophysiology*. 2018; 4: 987–995.
 - [47] Reddy VY, Anic A, Koruth J, Petru J, Funosako M, Minami K, *et al.* Pulsed Field Ablation in Patients With Persistent Atrial Fibrillation. *Journal of the American College of Cardiology*. 2020; 76: 1068–1080.
 - [48] Lemoine MD, Fink T, Mencke C, Schleberger R, My I, Obergassel J, *et al.* Pulsed-field ablation-based pulmonary vein isolation: acute safety, efficacy and short-term follow-up in a multi-center real world scenario. *Clinical Research in Cardiology*. 2023; 112: 795–806.
 - [49] Ruwald MH, Haugdal M, Worck R, Johannessen A, Hansen ML, Sørensen SK, *et al.* Characterization of durability and reconnection patterns at time of repeat ablation after single-shot pulsed field pulmonary vein isolation. *Journal of Interventional Cardiac Electrophysiology*. 2023. (online ahead of print)
 - [50] Magni FT, Scherr D, Manning M, Sohns C, Sommer P, Hovakimyan T, *et al.* Electrophysiological findings during re-do procedures after single-shot pulmonary vein isolation for atrial fibrillation with pulsed field ablation. *Journal of Interventional Cardiac Electrophysiology*. 2023; 66: 1729–1737.
 - [51] Kueffer T, Stefanova A, Madaffari A, Seiler J, Thalmann G, Kozhuharov N, *et al.* Pulmonary vein isolation durability and lesion regression in patients with recurrent arrhythmia after pulsed-field ablation. *Journal of Interventional Cardiac Electrophysiology*. 2023. (online ahead of print)

- [52] Lemoine M, Obergassel J, Rottner L, Moser F, My I, Wenzel JP, *et al.* Pulsed-field ablation based pulmonary vein isolation: reconnection pattern and comparison to cryoballoon ablation. *Europace*. 2023; 25: euad122–083.
- [53] Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, *et al.* Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. *Circulation*. 2023; 147: 1422–1432.
- [54] Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, *et al.* Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. *The New England Journal of Medicine*. 2023; 389: 1660–1671.
- [55] Baena-Montes JM, O'Halloran T, Clarke C, Donaghey K, Dunne E, O'Halloran M, *et al.* Electroporation Parameters for Human Cardiomyocyte Ablation In Vitro. *Journal of Cardiovascular Development and Disease*. 2022; 9: 240.
- [56] Maor E, Ivorra A, Rubinsky B. Non thermal irreversible electroporation: novel technology for vascular smooth muscle cells ablation. *PLoS ONE*. 2009; 4: e4757.
- [57] Avazzadeh S, O'Brien B, Coffey K, O'Halloran M, Keane D, Quinlan LR. Establishing Irreversible Electroporation Electric Field Potential Threshold in A Suspension In Vitro Model for Cardiac and Neuronal Cells. *Journal of Clinical Medicine*. 2021; 10: 5443.
- [58] Cindric H, Gasljevic G, Edhemovic I, Brecelj E, Zmuc J, Cemazar M, *et al.* Numerical mesoscale tissue model of electrochemotherapy in liver based on histological findings. *Scientific Reports*. 2022; 12: 6476.
- [59] Neal RE, 2nd, Garcia PA, Kavnaudias H, Rosenfeldt F, Mclean CA, Earl V, *et al.* In vivo irreversible electroporation kidney ablation: experimentally correlated numerical models. *IEEE Transactions on Bio-medical Engineering*. 2015; 62: 561–569.
- [60] Campelo S, Valerio M, Ahmed HU, Hu Y, Arena SL, Neal RE, 2nd, *et al.* An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements. *APL Bioengineering*. 2017; 1: 016101.
- [61] Kaminska I, Kotulska M, Stecka A, Saczko J, Drag-Zalesinska M, Wysocka T, *et al.* Electroporation-induced changes in normal immature rat myoblasts (H9C2). *General Physiology and Biophysics*. 2012; 31: 19–25.
- [62] Liu A, Lin M, Maduray K, Han W, Zhong JQ. Clinical Manifestations, Outcomes, and Mortality Risk Factors of Atrial-Esophageal Fistula: A Systematic Review. *Cardiology*. 2022; 147: 26–34.
- [63] Neven K, van Es R, van Driel V, van Wessel H, Fidder H, Vink A, *et al.* Acute and Long-Term Effects of Full-Power Electroporation Ablation Directly on the Porcine Esophagus. *Circulation. Arrhythmia and Electrophysiology*. 2017; 10: e004672.
- [64] Verma A, Asivatham SJ, Deneke T, Castellvi Q, Neal RE, 2nd. Primer on Pulsed Electrical Field Ablation: Understanding the Benefits and Limitations. *Circulation. Arrhythmia and Electrophysiology*. 2021; 14: e010086.
- [65] Koruth JS, Kuroki K, Kawamura I, Brose R, Viswanathan R, Buck ED, *et al.* Pulsed Field Ablation Versus Radiofrequency Ablation: Esophageal Injury in a Novel Porcine Model. *Circulation. Arrhythmia and Electrophysiology*. 2020; 13: e008303.
- [66] Hong J, Stewart MT, Cheek DS, Francischelli DE, Kirchhof N. Cardiac ablation via electroporation. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference*. 2009; 2009: 3381–3384.
- [67] Cochet H, Nakatani Y, Sridi-Cheniti S, Cheniti G, Ramirez FD, Nakashima T, *et al.* Pulsed field ablation selectively spares the esophagus during pulmonary vein isolation for atrial fibrillation. *Europace*. 2021; 23: 1391–1399.
- [68] Song Y, Zheng J, Fan L. Nonthermal Irreversible Electroporation to the Esophagus: Evaluation of Acute and Long-Term Pathological Effects in a Rabbit Model. *Journal of the American Heart Association*. 2021; 10: e020731.
- [69] Nery PB, Belliveau D, Nair GM, Bernick J, Redpath CJ, Szczołka A, *et al.* Relationship Between Pulmonary Vein Reconnection and Atrial Fibrillation Recurrence: A Systematic Review and Meta-Analysis. *JACC: Clinical Electrophysiology*. 2016; 2: 474–483.
- [70] Haïssaguerre M, Jaïs P, Shah DC, Garrigue S, Takahashi A, Lavergne T, *et al.* Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. *Circulation*. 2000; 101: 1409–1417.
- [71] Howard B, Haines DE, Verma A, Packer D, Kirchhof N, Barka N, *et al.* Reduction in Pulmonary Vein Stenosis and Collateral Damage With Pulsed Field Ablation Compared With Radiofrequency Ablation in a Canine Model. *Circulation. Arrhythmia and Electrophysiology*. 2020; 13: e008337.
- [72] van Es R, Konings MK, Du Pré BC, Neven K, van Wessel H, van Driel VJHM, *et al.* High-frequency irreversible electroporation for cardiac ablation using an asymmetrical waveform. *Biomedical Engineering Online*. 2019; 18: 75.
- [73] Kuroki K, Whang W, Eggert C, Lam J, Leavitt J, Kawamura I, *et al.* Ostial dimensional changes after pulmonary vein isolation: Pulsed field ablation vs radiofrequency ablation. *Heart Rhythm*. 2020; 17: 1528–1535.
- [74] Pothineni NV, Kancharla K, Katoor AJ, Shanta G, Paydak H, Kapa S, *et al.* Coronary artery injury related to catheter ablation of cardiac arrhythmias: A systematic review. *Journal of Cardiovascular Electrophysiology*. 2019; 30: 92–101.
- [75] Thyer IA, Kovoor P, Barry MA, Pouliopoulos J, Ross DL, Thiagalingam A. Protection of the coronary arteries during epicardial radiofrequency ablation with intracoronary chilled saline irrigation: assessment in an in vitro model. *Journal of Cardiovascular Electrophysiology*. 2006; 17: 544–549.
- [76] du Pré BC, Driel VJ, van Wessel H, Loh P, Doevendans PA, Goldschmeding R, *et al.* Minimal coronary artery damage by myocardial electroporation ablation. *Europace*. 2013; 15: 144–149.
- [77] Higuchi S, Im SI, Stillson C, Buck ED, Jerrell S, Schneider CW, *et al.* Effect of Epicardial Pulsed Field Ablation Directly on Coronary Arteries. *JACC. Clinical Electrophysiology*. 2022; 8: 1486–1496.
- [78] Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A, *et al.* Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). *Europace*. 2022; 24: 1256–1266.
- [79] Gunawardene MA, Schaeffer BN, Jularic M, Eickholt C, Maurer T, Akbulak RÖ, *et al.* Coronary Spasm During Pulsed Field Ablation of the Mitral Isthmus Line. *JACC. Clinical Electrophysiology*. 2021; 7: 1618–1620.
- [80] Davong B, Adeliño R, Delasnerie H, Albenque JP, Combes N, Cardin C, *et al.* Pulsed-Field Ablation on Mitral Isthmus in Persistent Atrial Fibrillation: Preliminary Data on Efficacy and Safety. *JACC. Clinical Electrophysiology*. 2023; 9: 1070–1081.
- [81] Reddy VY, Petru J, Funasako M, Kopriva K, Hala P, Chovanec M, *et al.* Coronary Arterial Spasm During Pulsed Field Ablation to Treat Atrial Fibrillation. *Circulation*. 2022; 146: 1808–1819.
- [82] Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. *Technology in Cancer Research & Treatment*. 2007; 6: 295–300.
- [83] Howard B, Haines DE, Verma A, Kirchhof N, Barka N, Onal B, *et al.* Characterization of Phrenic Nerve Response to Pulsed Field Ablation. *Circulation. Arrhythmia and Electrophysiology*. 2022; 15: e010127.
- [84] Guo F, Wang J, Deng Q, Feng H, Xie M, Zhou Z, *et al.* Effects of pulsed field ablation on autonomic nervous system in parox-

- ysmal atrial fibrillation: A pilot study. *Heart Rhythm*. 2023; 20: 329–338.
- [85] Pansera F, Bordignon S, Bologna F, Tohoku S, Chen S, Urbanek L, *et al.* Catheter ablation induced phrenic nerve palsy by pulsed field ablation-completely impossible? A case series. *European Heart Journal. Case Reports*. 2022; 6: ytac361.
- [86] Aldaas OM, Malladi C, Han FT, Hoffmayer KS, Krummen D, Ho G, *et al.* Pulsed field ablation versus thermal energy ablation for atrial fibrillation: a systematic review and meta-analysis of procedural efficiency, safety, and efficacy. *Journal of Interventional Cardiac Electrophysiology*. 2023. (online ahead of print)
- [87] Ramirez FD, Reddy VY, Viswanathan R, Hocini M, Jaïs P. Emerging Technologies for Pulmonary Vein Isolation. *Circulation Research*. 2020; 127: 170–183.
- [88] Schmidt B, Bordignon S, Tohoku S, Chen S, Bologna F, Urbanek L, *et al.* 5S Study: Safe and Simple Single Shot Pulmonary Vein Isolation With Pulsed Field Ablation Using Sedation. *Circulation. Arrhythmia and Electrophysiology*. 2022; 15: e010817.
- [89] Bordignon S, Chen S, Bologna F, Thohoku S, Urbanek L, Willems F, *et al.* Optimizing cryoballoon pulmonary vein isolation: lessons from >1000 procedures- the Frankfurt approach. *Europace*. 2021; 23: 868–877.
- [90] Schmidt B, Petru J, Chun KRJ, Sediva L, Bordignon S, Chen S, *et al.* Pivotal Study of a Novel Motor-Driven Endoscopic Ablation System. *Circulation. Arrhythmia and Electrophysiology*. 2021; 14: e009544.
- [91] Gunawardene MA, Schaeffer BN, Jularic M, Eickholt C, Maurer T, Akbulak RÖ, *et al.* Pulsed-field ablation combined with ultrahigh-density mapping in patients undergoing catheter ablation for atrial fibrillation: Practical and electrophysiological considerations. *Journal of Cardiovascular Electrophysiology*. 2022; 33: 345–356.
- [92] Tan HW, Wang XH, Shi HF, Zhou L, Gu JN, Liu X. Left atrial wall thickness: anatomic aspects relevant to catheter ablation of atrial fibrillation. *Chinese Medical Journal*. 2012; 125: 12–15.
- [93] Kawamura I, Neuzil P, Shivamurthy P, Petru J, Funasako M, Minami K, *et al.* Does pulsed field ablation regress over time? A quantitative temporal analysis of pulmonary vein isolation. *Heart Rhythm*. 2021; 18: 878–884.
- [94] Groen MHA, van Driel VJHM, Neven K, van Wessel H, de Bakker JMT, Doevdands PAF, *et al.* Multielectrode Contact Measurement Can Improve Long-Term Outcome of Pulmonary Vein Isolation Using Circular Single-Pulse Electroporation Ablation. *Circulation. Arrhythmia and Electrophysiology*. 2022; 15: e010835.
- [95] Kueffer T, Baldinger SH, Servatius H, Madaffari A, Seiler J, Mühl A, *et al.* Validation of a multipolar pulsed-field ablation catheter for endpoint assessment in pulmonary vein isolation procedures. *Europace*. 2022; 24: 1248–1255.
- [96] Nakatani Y, Sridi-Cheniti S, Cheniti G, Ramirez FD, Goujeau C, André C, *et al.* Pulsed field ablation prevents chronic atrial fibrotic changes and restrictive mechanics after catheter ablation for atrial fibrillation. *Europace*. 2021; 23: 1767–1776.
- [97] Bohnen M, Weber R, Minners J, Jadidi A, Eichenlaub M, Neumann FJ, *et al.* Characterization of circumferential antral pulmonary vein isolation areas resulting from pulsed-field catheter ablation. *Europace*. 2023; 25: 65–73.
- [98] Koruth JS, Kuroki K, Iwasawa J, Viswanathan R, Brose R, Buck ED, *et al.* Endocardial ventricular pulsed field ablation: a proof-of-concept preclinical evaluation. *Europace*. 2020; 22: 434–439.
- [99] Neven K, Fütting A, Byrd I, Heil RW, Jr, Fish JM, Feeney DA, *et al.* Absence of (sub-)acute cerebral events or lesions after electroporation ablation in the left-sided canine heart. *Heart Rhythm*. 2021; 18: 1004–1011.
- [100] Reinsch N, Fütting A, Höwel D, Bell J, Lin Y, Neven K. Cerebral safety after pulsed field ablation for paroxysmal atrial fibrillation. *Heart Rhythm*. 2022; 19: 1813–1818.
- [101] Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, *et al.* Safety and Effectiveness of Pulsed Field Ablation to Treat Atrial Fibrillation: One-Year Outcomes From the MANIFEST-PF Registry. *Circulation*. 2023; 148: 35–46.
- [102] Wijesurendra RS, Liu A, Notaristefano F, Ntusi NAB, Karamitsos TD, Bashir Y, *et al.* Myocardial Perfusion Is Impaired and Relates to Cardiac Dysfunction in Patients With Atrial Fibrillation Both Before and After Successful Catheter Ablation. *Journal of the American Heart Association*. 2018; 7: e009218.
- [103] González-Suárez A, Pérez JJ, O'Brien B, Elahi A. In Silico Modelling to Assess the Electrical and Thermal Disturbance Provoked by a Metal Intracoronary Stent during Epicardial Pulsed Electric Field Ablation. *Journal of Cardiovascular Development and Disease*. 2022; 9: 458.
- [104] Winkelmann SJ, Lemoine MD, Wuerger T, Schleberger R, Rottner L, Dinshaw L, *et al.* Safety of pulsed-field ablation in patients with cardiac implantable electronic devices. A single-center pilot study. *Europace*. 2022; 24: euac053–234.
- [105] Weyand S, Löbig S, Seizer P. First in human focal pulsed field ablation to treat an epicardial VT focus with an endocardial approach in non-ischemic cardiomyopathy. *Journal of Interventional Cardiac Electrophysiology*. 2023; 66: 1057–1058.
- [106] Chen S, Chun JKR, Bordignon S, Tohoku S, Urbanek L, Schaack D, *et al.* Pulsed field ablation-based pulmonary vein isolation in atrial fibrillation patients with cardiac implantable electronic devices: practical approach and device interrogation (PFA in CIEDs). *Journal of Interventional Cardiac Electrophysiology*. 2023; 66: 1929–1938.
- [107] Dunki-Jacobs EM, Philips P, Martin RCG, 2nd. Evaluation of thermal injury to liver, pancreas and kidney during irreversible electroporation in an in vivo experimental model. *The British Journal of Surgery*. 2014; 101: 1113–1121.
- [108] van den Bos W, Scheffer HJ, Vogel JA, Wagstaff PGK, de Bruin DM, de Jong MC, *et al.* Thermal Energy during Irreversible Electroporation and the Influence of Different Ablation Parameters. *Journal of Vascular and Interventional Radiology*. 2016; 27: 433–443.
- [109] Yavin H, Shapira-Daniels A, Barkagan M, Sroubek J, Shim D, Melidone R, *et al.* Pulsed Field Ablation Using a Lattice Electrode for Focal Energy Delivery: Biophysical Characterization, Lesion Durability, and Safety Evaluation. *Circulation. Arrhythmia and Electrophysiology*. 2020; 13: e008580.
- [110] Ji X, Zhang H, Zang L, Yan S, Wu X. The Effect of Discharge Mode on the Distribution of Myocardial Pulsed Electric Field-A Simulation Study for Pulsed Field Ablation of Atrial Fibrillation. *Journal of Cardiovascular Development and Disease*. 2022; 9: 95.
- [111] Roney CH, Cantwell CD, Bayer JD, Qureshi NA, Lim PB, Tweedy JH, *et al.* Spatial Resolution Requirements for Accurate Identification of Drivers of Atrial Fibrillation. *Circulation. Arrhythmia and Electrophysiology*. 2017; 10: e004899.
- [112] Mattison L, Verma A, Tarakji KG, Reichlin T, Hindricks G, Sack KL, *et al.* Effect of contact force on pulsed field ablation lesions in porcine cardiac tissue. *Journal of Cardiovascular Electrophysiology*. 2023; 34: 693–699.
- [113] Howard B, Verma A, Tzou WS, Mattison L, Kos B, Miklavčič D, *et al.* Effects of Electrode-Tissue Proximity on Cardiac Lesion Formation Using Pulsed Field Ablation. *Circulation. Arrhythmia and Electrophysiology*. 2022; 15: e011110.
- [114] Wardhana G, Raman NM, Abayazid M, Fütterer JJ. Investigating the effect of electrode orientation on irreversible electroporation with experiment and simulation. *International Journal of Computer Assisted Radiology and Surgery*. 2022; 17: 1399–1407.
- [115] Ye X, Liu S, Yin H, He Q, Xue Z, Lu C, *et al.* Study on Optimal

- Parameter and Target for Pulsed-Field Ablation of Atrial Fibrillation. *Frontiers in Cardiovascular Medicine*. 2021; 8: 690092.
- [116] Zang L, Gu K, Ji X, Zhang H, Yan S, Wu X. Effect of Anisotropic Electrical Conductivity Induced by Fiber Orientation on Ablation Characteristics of Pulsed Field Ablation in Atrial Fibrillation Treatment: A Computational Study. *Journal of Cardiovascular Development and Disease*. 2022; 9: 319.
- [117] Di Biase L, Natale A, Romero J. Thrombogenic and Arrhythmogenic Roles of the Left Atrial Appendage in Atrial Fibrillation. *Circulation*. 2018; 138: 2036–2050.
- [118] Stojadinović P, Wichterle D, Peichl P, Nakagawa H, Čihák R, Hašková J, *et al*. Autonomic Changes Are More Durable After Radiofrequency Than Pulsed Electric Field Pulmonary Vein Ablation. *JACC. Clinical Electrophysiology*. 2022; 8: 895–904.
- [119] Musikantow DR, Neuzil P, Petru J, Koruth JS, Kralovec S, Miller MA, *et al*. Pulsed Field Ablation to Treat Atrial Fibrillation: Autonomic Nervous System Effects. *JACC. Clinical Electrophysiology*. 2023; 9: 481–493.
- [120] Kaba RA, Momin A, Camm J. Persistent Atrial Fibrillation: The Role of Left Atrial Posterior Wall Isolation and Ablation Strategies. *Journal of Clinical Medicine*. 2021; 10: 3129.
- [121] Tomlinson DR, Mandrola J. Pulsed Field Ablation for Persistent Atrial Fibrillation (PersAFOne): Hope or Hype? *Journal of the American College of Cardiology*. 2020; 76: 1081–1083.
- [122] Kim JS, Shin SY, Na JO, Choi CU, Kim SH, Kim JW, *et al*. Does isolation of the left atrial posterior wall improve clinical outcomes after radiofrequency catheter ablation for persistent atrial fibrillation?: A prospective randomized clinical trial. *International Journal of Cardiology*. 2015; 181: 277–283.
- [123] Kueffer T, Madaffari A, Muehl A, Seiler J, Thalmann G, Servatius H, *et al*. Initial experience and early outcomes of posterior wall ablation using pulsed-field ablation. *Europace*. 2023; 25: eua122–158.
- [124] Derval N, Duchateau J, Denis A, Ramirez FD, Mahida S, André C, *et al*. Marshall bundle elimination, Pulmonary vein isolation, and Line completion for Anatomical ablation of persistent atrial fibrillation (Marshall-PLAN): Prospective, single-center study. *Heart Rhythm*. 2021; 18: 529–537.
- [125] Kueffer T, Seiler J, Madaffari A, Mühl A, Asatryan B, Stettler R, *et al*. Pulsed-field ablation for the treatment of left atrial reentry tachycardia. *Journal of Interventional Cardiac Electrophysiology*. 2023; 66: 1431–1440.
- [126] Lee S, Sahadevan J, Khrestian CM, Cakulev I, Markowitz A, Waldo AL. Simultaneous Batrial High-Density (510-512 Electrodes) Epicardial Mapping of Persistent and Long-Standing Persistent Atrial Fibrillation in Patients: New Insights Into the Mechanism of Its Maintenance. *Circulation*. 2015; 132: 2108–2117.
- [127] Wang W, Tian Y, Wang W, Yin H, Yin D, *et al*. Role of Epicardial Adipose Tissue in Triggering and Maintaining Atrial Fibrillation. *Cardiovascular Innovations and Applications*. 2022.
- [128] Verma A, Feld GK, Cox JL, Dewland TA, Babkin A, De Potter T, *et al*. Combined pulsed field ablation with ultra-low temperature cryoablation: A preclinical experience. *Journal of Cardiovascular Electrophysiology*. 2023; 34: 2124–2133.
- [129] Schuessler RB, Lee AM, Melby SJ, Voeller RK, Gaynor SL, Sakamoto SI, *et al*. Animal studies of epicardial atrial ablation. *Heart Rhythm*. 2009; 6: S41–S45.
- [130] de Groot NMS, Houben RPM, Smeets JL, Boersma E, Schotten U, Schalij MJ, *et al*. Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: epicardial breakthrough. *Circulation*. 2010; 122: 1674–1682.
- [131] Parameswaran R, Kalman JM, Royse A, Goldblatt J, Larobina M, Watts T, *et al*. Endocardial-Epicardial Phase Mapping of Prolonged Persistent Atrial Fibrillation Recordings: High Prevalence of Dissociated Activation Patterns. *Circulation. Arrhythmia and Electrophysiology*. 2020; 13: e008512.
- [132] Walters TE, Lee G, Lee A, Sievers R, Kalman JM, Gerstenfeld EP. Site-Specific Epicardium-to-Endocardium Dissociation of Electrical Activation in a Swine Model of Atrial Fibrillation. *JACC. Clinical Electrophysiology*. 2020; 6: 830–845.
- [133] Mao J, Yin X, Zhang Y, Yan Q, Dong J, Ma C, *et al*. Ablation of epicardial ganglionated plexi increases atrial vulnerability to arrhythmias in dogs. *Circulation. Arrhythmia and Electrophysiology*. 2014; 7: 711–717.
- [134] Neven K, van Driel V, van Wessel H, van Es R, Doevendans PA, Wittkamp F. Myocardial lesion size after epicardial electroporation catheter ablation after subxiphoid puncture. *Circulation. Arrhythmia and Electrophysiology*. 2014; 7: 728–733.
- [135] Musikantow DR, Reddy VY, Skalsky I, Shaburishvili T, van Zyl M, O'Brien B, *et al*. Targeted ablation of epicardial ganglionated plexi during cardiac surgery with pulsed field electroporation (NEURAL AF). *Journal of Interventional Cardiac Electrophysiology*. 2023. (online ahead of print)
- [136] González-Suárez A, O'Brien B, O'Halloran M, Elahi A. Pulsed Electric Field Ablation of Epicardial Autonomic Ganglia: Computer Analysis of Monopolar Electric Field across the Tissues Involved. *Bioengineering*. 2022; 9: 731.
- [137] González-Suárez A, Irastorza RM, Deane S, O'Brien B, O'Halloran M, Elahi A. Full torso and limited-domain computer models for epicardial pulsed electric field ablation. *Computer Methods and Programs in Biomedicine*. 2022; 221: 106886.